Latest News for: -ose

Edit

Railway staff reappraisals underway, two OSE trainee drug-related dismissals

Ekathimerini 03 Apr 2025
According to OSE, the dismissed individuals were among 109 trainees preparing for station-master positions but had not yet begun their roles. The two men, OSE has informed, were not on the company’s ...
Edit

OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 (OSE Immunotherapeutics SA)

Public Technologies 03 Apr 2025
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 OSE-CYTOMASK®, a new CIS-Demasking 1 cytokine bispecific technology ... CET - OSE Immunotherapeutics SA (ISIN ... ABOUT OSE IMMUNOTHERAPEUTICS.
Edit

03/04/2025 OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025 (OSE Immunotherapeutics SA)

Public Technologies 03 Apr 2025
OSE Immunotherapeutics Presents Preclinical Updates in Immuno-Oncology at AACR Annual Meeting 2025. • OSE-CYTOMASK®, a new CIS-Demasking1 cytokine bispecific technology ... CET - OSE Immunotherapeutics SA (ISIN ... ABOUT OSE IMMUNOTHERAPEUTICS.
Edit

Lokotech Group AS (OSE: LOKO) Meldingspliktig handel (Lokotech Group AS)

Public Technologies 02 Apr 2025
). The text version of this document is not available ... Disclaimer ... (noodl. 123434994) .
Edit

OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (OSE Immunotherapeutics SA)

Public Technologies 26 Mar 2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update ... CET - OSE Immunotherapeutics SA (ISIN ... OSE Immunotherapeutics and Boehringer Ingelheim announced a major expansion of their partnership ... Tedopi® + OSE-279.
Edit

26/03/2025 OSE Immunotherapeutics Reports Full Year 2024 Financial Results and Provides Corporate Update (OSE Immunotherapeutics SA)

Public Technologies 26 Mar 2025
OSE Immunotherapeutics Reports Full Year 2024 Financial Results and ... CET - OSE Immunotherapeutics SA (ISIN ... "2024 was transformative for OSE, marked by positive efficacy results, major partnerships, and accelerated preclinical programs.
  • 1
×